Financial SupportCKLS has agreed to loan $19.5M to the newly created Dogwood Therapeutics, potentially extending the company's cash runway into 2026.
Market OpportunityThe U.S. market for Long COVID alone could reach several million patients, and the lack of any specifically approved therapies means success in this study could be a major catalyst for the stock.
Pipeline ExpansionThe merger with Wex Pharmaceuticals introduces Halneuron, a promising non-opioid painkiller that has shown positive results in clinical trials, to the company's product pipeline.